TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05976360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (SAR231893)
Description: Injection solution, subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab (SAR231893)
Description: Injection solution, subcutaneous.
Study: NCT03071120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Mediated Intervention
Description: Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
Study: NCT03743272

Intervention type: DEVICE
Intervention: LiverMultiScan
Description: Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.

Intervention type: DEVICE
Intervention: LiverMultiScan
Description: Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Study: NCT04325672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.
Study: NCT04408313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-B
Description: Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX
Description: Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
Study: NCT01761916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLONIDINE
Description: Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPTOPRIL
Description: Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
Study: NCT01691534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (J)
Description: TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (J)
Description: TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (J)
Description: TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (J)
Description: TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 (PA)
Description: PA-824 200mg Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 (PA)
Description: PA-824 200mg Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 (PA)
Description: PA-824 200mg Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide (Z)
Description: 1500mg Days 1-14 Dosed by Weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide (Z)
Description: 1500mg Days 1-14 Dosed by Weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide (Z)
Description: 1500mg Days 1-14 Dosed by Weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide (Z)
Description: 1500mg Days 1-14 Dosed by Weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofazimine (C)
Description: clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofazimine (C)
Description: clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofazimine (C)
Description: clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofazimine (C)
Description: clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour e-275 mg dosed by weight
Study: NCT04686474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachta indica leaves extract containing ointment intervention.
Description: Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
Study: NCT02211560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03668873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Parent Training
Description: SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Parent Education
Description: SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
Study: NCT01514799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass
Description: two techniques of gastric bypass for studying the effects of making a long BP-limb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: two techniques of gastric bypass for studying the effects of making a long BP-limb
Study: NCT01855529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine in one arm and placebo (NaCl) in the other arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine in one arm and placebo (NaCl) in the other arm
Study: NCT00541372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin injection needle size
Description: The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: insulin injection needle size
Description: The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
Study: NCT02453620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT01614249

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soybean oil soft gels
Description: Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 EPA-rich soft gels
Description: A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
Study: NCT01282034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow stimulation - Drilling or Microfractures
Description: Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaioRegen Surgery
Description: MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
Study: NCT01239199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of the exhaled NO
Description: The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
Study: NCT02265458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical intervention and sensory isolation
Description: 30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Musical intervention and sensory isolation
Description: 30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
Study: NCT02938130

Intervention type: OTHER
Intervention: Wellness Programs
Description: Wellness Programs delivered in the Community Partners and Community LIFE programs
Study: NCT03896438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
Study: NCT04106297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Placebo for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 capsule
Description: GLPG3970 for oral administration
Study: NCT04609943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1211163
Description: Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
Study: NCT02595892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03796650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 50 g donor feces suspended in saline with added glycerol, administered by a enema kit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Peroral vancomycin 125 mg q.i.d. for ten days.
Study: NCT00980954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenously

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Daily fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard external beam radiation therapy
Description: Daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard external beam radiation therapy
Description: Daily fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Optional brachytherapy boost
Description: Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Optional brachytherapy boost
Description: Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.
Study: NCT02615600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lf-tRNS
Description: Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
Study: NCT02331056

Intervention type: OTHER
Intervention: fluid loading
Description: Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records.

Intervention type: OTHER
Intervention: fluid loading
Description: Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records.

Intervention type: PROCEDURE
Intervention: thoracoscopic pulmonary lobectomy
Description: the patient group for scheduled thoracoscopic pulmonary lobectomy

Intervention type: PROCEDURE
Intervention: thoracotomy
Description: the patient group for scheduled open pulmonary lobectomy
Study: NCT02432443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and pre-literacy program
Description: The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Comparison
Description: The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
Study: NCT02825498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact force guided RFA
Description: Contact force guided RFA during Atrial Flutter ablation procedure.
Study: NCT00829569

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intralipid +/- Omegaven
Description: Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).
Study: NCT00236223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin + dexamethasone + ketamine
Description: Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00474812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiologic testing
Description: Correlative study
Study: NCT00685230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) equine immune F(ab)2
Description: 3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo reconstituted in 50 ml of normal saline administered over 10 min
Study: NCT00619034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost, diclofenac and dorzolamide (eyedrops)
Description: 1 eyedrop twice daily in one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: dicolfenac eyedrops twice daily i one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Description: dorzolamide eyedrops twice daily, in one eye for one week
Study: NCT02873858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smell and taste tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smell and taste tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smell and taste tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smell and taste tests
Study: NCT02586181

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D and Calcium
Description: a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, Calcium, Vitamins B9, B6, B12
Description: a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12
Study: NCT01022060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renalof
Description: One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
Study: NCT03851835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Oral Solution
Description: Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Study: NCT03241732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-inflammatory Diet
Description: Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: Intravenous and Oral n-acetyl cysteine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Emotive Technique
Description: Neuro Emotive Technique sessions
Study: NCT04126161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: standard of care CT prior to primary hip replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan together with standard of care CT prior to primary hip replacement